Spero Therapeutics: R&D Day on Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD) and Spero’s SPR720 Program
About The Event
The virtual R&D Day will feature a presentation by key opinion leader Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical School).
During his presentation, Dr. Winthrop will discuss the etiology, unmet medical need, and treatment landscape of NTM-PD. Members of the Spero management team will provide an overview of the development program for SPR720, a potential novel first line oral therapy for NTM infections.
A live Q&A session will follow the formal presentations.